0001179110-19-002360.txt : 20190222
0001179110-19-002360.hdr.sgml : 20190222
20190222171605
ACCESSION NUMBER: 0001179110-19-002360
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190221
FILED AS OF DATE: 20190222
DATE AS OF CHANGE: 20190222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Durkin Brian L
CENTRAL INDEX KEY: 0001756865
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 19626680
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
edgar.xml
FORM 4 -
X0306
4
2019-02-21
0
0001551152
AbbVie Inc.
ABBV
0001756865
Durkin Brian L
1 NORTH WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
0
1
0
0
VP, Controller
Common stock, $0.01 par value
2019-02-21
4
A
0
1213
0
A
5464
D
Common stock, $0.01 par value
2019-02-21
4
A
0
874
0
A
7159
D
Common stock, $0.01 par value
2019-02-21
4
A
0
1074
0
A
8869
D
Common stock, $0.01 par value
2019-02-21
4
A
0
576
0
A
10354
D
Common stock, $0.01 par value
253
I
By spouse
Option (right to buy)
79.02
2019-02-21
4
A
0
11682
0
A
2020-02-21
2029-02-20
Common Stock
11682
11682
D
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
The reporting person disclaims beneficial ownership of all securities held by his spouse.
Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,894 on February 21, 2020, 3,894 on February 21, 2021, and 3,894 on February 21, 2022.
Steven Scrogham, attorney-in-fact for Brian L. Durkin
2019-02-22